减肥药物开发商 Metsera 筹集了 2.9 亿美元资金，由 ARCH Venture Partners 领投，用于使用 GLP-1 机制治疗肥胖症。 Weight-loss drug developer Metsera raises $290M in funding, led by ARCH Venture Partners, for obesity treatments using GLP-1 mechanism.
减肥药物开发商 Metsera 已筹集 2.9 亿美元资金，由生物技术投资者 ARCH Venture Partners 领投。 Weight-loss drug developer Metsera has raised $290 million in funding, led by biotech investor ARCH Venture Partners. 该公司正在利用GLP-1机制和其他生物靶点开发治疗肥胖症的注射和口服药物。 The company is developing injectable and oral drugs for obesity using the GLP-1 mechanism and other biological targets. Metsera 的 GLP-1 产品组合包括处于早期试验阶段的注射剂。 Metsera's GLP-1 portfolio includes an injectable in early trial stages. 预计到本世纪末减肥药市场规模将达到至少 1000 亿美元。 The market for weight-loss drugs is expected to reach at least $100 billion by the end of the decade.